The evolving role of receptors as predictive biomarkers for metastatic breast cancer

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Abstract P3-08-16: ER, PR and HER2 biomarkers in UK and Irish clinical breast cancer testing: analysis of results from >168,000 patients

(2018) A Dodson et al.   CANCER RESEARCH

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

(2018) MN Dickler et al.   CANCER RESEARCH

An update on first line therapies for metastatic breast cancer

(2018) Palma Fedele et al.   EXPERT OPINION ON PHARMACOTHERAPY

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients

(2018) Alexey A. Larionov   Frontiers in Oncology

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

Efficacy of Trastuzumab in Unselected Patients with HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis

(2018) Elena Collovà et al.   TUMORI

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

(2017) M.J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases

(2017) Gabriele Zoppoli et al.   Journal of Translational Medicine

HER2-positive breast cancer

(2017) Sibylle Loibl et al.   LANCET

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

(2017) Antonio Llombart-Cussac et al.   LANCET ONCOLOGY

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients

(2017) Nick Beije et al.   Molecular Oncology

Prognostic and predictive biomarkers in breast cancer: Past, present and future

(2017) Andrea Nicolini et al.   SEMINARS IN CANCER BIOLOGY

Molecular heterogeneity in breast cancer: State of the science and implications for patient care

(2017) Rachel E. Ellsworth et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients

(2017) Takashi Takeshita et al.   Translational Oncology

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer

(2017) Kazuhiro Araki et al.   Breast Cancer

An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

(2017) Ariella B. Hanker et al.   Cancer Discovery

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients

(2017) Takashi Takeshita et al.   Oncotarget

Fulvestrant in advanced breast cancer: evidence to date and place in therapy

(2017) Katalin Boér   Therapeutic Advances in Medical Oncology

Correlation between IHC and FISH for HER2/neu assessment in patients with breast cancer

(2017) S. Vigo et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

(2016) S. Loibl et al.   ANNALS OF ONCOLOGY

Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less

(2016) Angela Toss et al.   BREAST

Validated biomarkers: The key to precision treatment in patients with breast cancer

(2016) Michael J. Duffy et al.   BREAST

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling

(2016) Luca Gelsomino et al.   BREAST CANCER RESEARCH AND TREATMENT

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

(2016) Anna Nordenskjöld et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract OT1-02-02: The DETECT study program – Personalized treatment in metastatic breast cancer based on circulating tumor cells

(2016) A Schramm et al.   CANCER RESEARCH

Tumor Heterogeneity--A 'Contemporary Concept Founded on Historical Insights and Predictions

(2016) D. R. Welch   CANCER RESEARCH

Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer

(2016) J S Carroll   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

(2016) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

(2016) Alessandra Fabi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Metastatic breast cancer: The Odyssey of personalization

(2016) A. Sonnenblick et al.   Molecular Oncology

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

(2016) Serena Nik-Zainal et al.   NATURE

ESR1 -Amplification-Associated Estrogen Receptor α Activity in Breast Cancer

(2016) Frederik Holst et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

(2016) Jill M. Spoerke et al.   Nature Communications

ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists

(2016) Weiyi Toy et al.   Cancer Discovery

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells

(2016) Xiuwen Guan et al.   Oncotarget

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

(2016) Debora de Melo Gagliato et al.   Oncotarget

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer

(2016) Sarat Chandarlapaty et al.   JAMA Oncology

Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies

(2016) Dominic A. Pearce et al.   Scientific Reports

Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1

(2015) Daniela Furrer et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors

(2015) Camille Petrau et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Targeting HER2 for the Treatment of Breast Cancer

(2015) Mothaffar F. Rimawi et al.   Annual Review of Medicine

RAD1901

(2015) Fiona Garner et al.   ANTI-CANCER DRUGS

Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer

(2015) Savas D. Soysal et al.   BREAST CANCER RESEARCH AND TREATMENT

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SEOM clinical guidelines in metastatic breast cancer 2015

(2015) J. Gavilá et al.   Clinical & Translational Oncology

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

(2015) D. Chu et al.   CLINICAL CANCER RESEARCH

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

(2015) S. E. Wardell et al.   CLINICAL CANCER RESEARCH

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

(2015) P. Wang et al.   CLINICAL CANCER RESEARCH

Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer

(2015) D. S. Guttery et al.   CLINICAL CHEMISTRY

A multiplex allele-specific real-time PCR assay for screening of ESR1 mutations in metastatic breast cancer

(2015) Ting Wang et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Short report: MonitoringESR1mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

(2015) David Sefrioui et al.   INTERNATIONAL JOURNAL OF CANCER

Intrinsic Subtypes,PIK3CAMutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial

(2015) Katherine L. Pogue-Geile et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2015) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

(2015) Maria Schwaederle et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

(2015) Andiliy Lai et al.   JOURNAL OF MEDICINAL CHEMISTRY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Endocrine resistance in breast cancer – An overview and update

(2015) Robert Clarke et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Progesterone receptor modulates ERα action in breast cancer

(2015) Hisham Mohammed et al.   NATURE

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology

Clinical management of breast cancer heterogeneity

(2015) Dimitrios Zardavas et al.   Nature Reviews Clinical Oncology

Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics

(2015) H. Gilbert Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials

(2015) M. Hicks et al.   ONCOLOGIST

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

(2015) Gaia Schiavon et al.   Science Translational Medicine

Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens

(2015) Takashi Takeshita et al.   Translational Research

Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ

(2015) Yasuaki Sagara et al.   JAMA Surgery

ESR1 Amplification is Rare in Breast Cancer and is Associated with High Grade and High Proliferation: A Multiplex Ligation-Dependent Probe Amplification Study

(2015) Cathy B. Moelans et al.   Analytical Cellular Pathology

Molecular Differences between Ductal CarcinomaIn Situand Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification Study

(2015) Cathy B. Moelans et al.   Analytical Cellular Pathology

Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research

(2014) P. K. Grover et al.   ANNALS OF ONCOLOGY

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

(2014) F. Cardoso et al.   ANNALS OF ONCOLOGY

Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies

(2014) Jessica Salmen et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer

(2014) IA Mayer et al.   CANCER RESEARCH

Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1

(2014) Y. Wang et al.   CANCER RESEARCH

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses

(2014) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool

(2014) J. F. Huggett et al.   CLINICAL CHEMISTRY

Sequence Artifacts in DNA from Formalin-Fixed Tissues: Causes and Strategies for Minimization

(2014) H. Do et al.   CLINICAL CHEMISTRY

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

(2014) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated UK Recommendations for HER2 assessment in breast cancer

(2014) Emad A Rakha et al.   JOURNAL OF CLINICAL PATHOLOGY

A community effort to assess and improve drug sensitivity prediction algorithms

(2014) James C Costello et al.   NATURE BIOTECHNOLOGY

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

(2014) Aaron M Newman et al.   NATURE MEDICINE

Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer

(2014) Z. Eroglu et al.   ONCOLOGIST

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Treatment of HER2-positive breast cancer

(2013) Maria Cristina Figueroa-Magalhães et al.   BREAST

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

(2013) Edith A. Perez et al.   BREAST CANCER RESEARCH AND TREATMENT

D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

(2013) K. Merenbakh-Lamin et al.   CANCER RESEARCH

Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?

(2013) K. Pantel et al.   CANCER RESEARCH

HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact

(2013) Natalie H. Turner et al.   CANCER TREATMENT REVIEWS

HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials

(2013) Susan Dent et al.   CANCER TREATMENT REVIEWS

HER2 testing: Current status and future directions

(2013) Edith A. Perez et al.   CANCER TREATMENT REVIEWS

Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease

(2013) S. E. Wardell et al.   CLINICAL CANCER RESEARCH

A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases

(2013) Gaetano Aurilio et al.   EUROPEAN JOURNAL OF CANCER

Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens

(2013) Andrew G. Hadd et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Use of SERMs for treatment in postmenopausal women

(2013) JoAnn V. Pinkerton et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Liquid biopsy: monitoring cancer-genetics in the blood

(2013) Emily Crowley et al.   Nature Reviews Clinical Oncology

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

(2013) Shunqiang Li et al.   Cell Reports

The Life History of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Breast cancer intratumor genetic heterogeneity: causes and implications

(2012) Charlotte KY Ng et al.   Expert Review of Anticancer Therapy

ESR1 amplification in breast cancer: controversy resolved?

(2012) Donna G Albertson   JOURNAL OF PATHOLOGY

Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?

(2012) Lauren T. Greer et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

(2012) Hyesil Seol et al.   MODERN PATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of ultra-rare mutations by next-generation sequencing

(2012) M. W. Schmitt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

p95HER2 and Breast Cancer

(2011) J. Arribas et al.   CANCER RESEARCH

Tumor Metastasis: Molecular Insights and Evolving Paradigms

(2011) Scott Valastyan et al.   CELL

Tumour seeding following percutaneous needle biopsy: The real story!

(2011) E.G. Robertson et al.   CLINICAL RADIOLOGY

Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

(2011) D. Hompes et al.   EJSO

Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study

(2011) Akishi Ooi et al.   JOURNAL OF PATHOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Detection and quantification of rare mutations with massively parallel sequencing

(2011) I. Kinde et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1

(2011) Anita K. Dunbier et al.   PLoS Genetics

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

(2010) Francisco J. Esteva et al.   AMERICAN JOURNAL OF PATHOLOGY

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

(2010) Ruth E. Board et al.   BREAST CANCER RESEARCH AND TREATMENT

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

(2010) J. Sperinde et al.   CLINICAL CANCER RESEARCH

Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease

(2010) Rena Callahan et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis

(2010) Vanya Van Belle et al.   JOURNAL OF CLINICAL ONCOLOGY

Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis

(2010) Evangelos Tsiambas et al.   MEDICAL ONCOLOGY

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes

(2010) Cathy B Moelans et al.   MODERN PATHOLOGY

Genomic rearrangements in inherited disease and cancer

(2010) Jian-Min Chen et al.   SEMINARS IN CANCER BIOLOGY

Massively Parallel Sequencing: The Next Big Thing in Genetic Medicine

(2009) Tracy Tucker et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

(2009) Y. Kataoka et al.   ANNALS OF ONCOLOGY

Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR

(2009) Anieta M. Sieuwerts et al.   BREAST CANCER RESEARCH AND TREATMENT

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients

(2009) Shuzhen Liu et al.   BREAST CANCER RESEARCH AND TREATMENT

Oestrogen receptor splice variants in the pathogenesis of disease

(2009) Siân E. Taylor et al.   CANCER LETTERS

Estrogen receptor α geneESR1amplification may predict endocrine therapy responsiveness in breast cancer patients

(2009) Saori Tomita et al.   CANCER SCIENCE

Resistance to Trastuzumab in Breast Cancer

(2009) P. R. Pohlmann et al.   CLINICAL CANCER RESEARCH

Genomic rearrangements in BRCA1 and BRCA2: a literature review

(2009) Ingrid Petroni Ewald et al.   GENETICS AND MOLECULAR BIOLOGY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer seeding associated with core needle biopsies: A systematic review

(2009) Fabienne Liebens et al.   MATURITAS

Complex landscapes of somatic rearrangement in human breast cancer genomes

(2009) Philip J. Stephens et al.   NATURE

Mutation Detection by Real-Time PCR: A Simple, Robust and Highly Selective Method

(2009) John Morlan et al.   PLoS One

Prognostic factors in 1038 women with metastatic breast cancer

(2008) R. Largillier et al.   ANNALS OF ONCOLOGY

The Genomic Heritage of Lymph Node Metastases: Implications for Clinical Management of Patients with Breast Cancer

(2008) Tyson E. Becker et al.   ANNALS OF SURGICAL ONCOLOGY

Molecular profiles of progesterone receptor loss in human breast tumors

(2008) Chad J. Creighton et al.   BREAST CANCER RESEARCH AND TREATMENT

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

(2008) Grazia Arpino et al.   ENDOCRINE REVIEWS

Absence of ESR1 amplification in a series of breast cancers

(2008) José Adélaïde et al.   INTERNATIONAL JOURNAL OF CANCER

Next-generation DNA sequencing

(2008) Jay Shendure et al.   NATURE BIOTECHNOLOGY

ESR1 gene amplification in breast cancer: a common phenomenon?

(2008) Anne Vincent-Salomon et al.   NATURE GENETICS

ESR1 gene amplification in breast cancer: a common phenomenon?

(2008) Jorge S Reis-Filho et al.   NATURE GENETICS

Reply to “ESR1 gene amplification in breast cancer: a common phenomenon?”

(2008) Frederik Holst et al.   NATURE GENETICS

Conflicting evidence on the frequency of ESR1 amplification in breast cancer

(2008) Donna G Albertson   NATURE GENETICS

ESR1 gene amplification in breast cancer: a common phenomenon?

(2008) Lindsay A Brown et al.   NATURE GENETICS

ESR1 gene amplification in breast cancer: a common phenomenon?

(2008) Hugo M Horlings et al.   NATURE GENETICS